Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
Items 401–500 of 743
Precision medicine in primary biliary cholangitis
Ronca, V., Gerussi, A., Cristoferi, L., Carbone, M., & Invernizzi, P. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12787 · Cited by 9
“The most commonly used diagnostic criteria, the Paris criteria, require the presence of at least two of three key features of both PBC and AIH to confirm the diagnosis.(11) For those who meet the Paris criteria, current European guidelines recommend the use of corticosteroids combined with azathioprine from the beginn…”
MethodPrimary biliary cholangitis: review for radiologists
Morgan, M. A., & Sundaram, K. M. (2021) · Abdominal Radiology · doi:10.1007/s00261-021-03335-x · Cited by 9
“This is thought to occur in 8–10% of patients, given the limitation that although there is expert consensus criteria for this diagnosis [35], there is no universally accepted set of criteria for the diagnosis.”
BackgroundFloreani, A., Baragiotta, A. M., & Guido, M. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00010-0 · Cited by 9
Cheung, K. S., Seto, W., Fung, J., Mak, L., Lai, C., & Yuen, M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i44.7863 · Cited by 10
Renou, C., Bourlière, M., Martini, F., Ouzan, D., Pénaranda, G., Larroque, O., Harafa, A., Igual, J., Calvet, B., Sokolowsky, S., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04252.x · Cited by 9
Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis
Shin, S., Moh, I. H., Woo, Y. S., Jung, S. W., Kim, J. B., Park, J. W., Suk, K. T., Kim, H. S., Hong, M., Park, S. H., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i39.7191 · Cited by 8
Histopathology of Autoimmune Hepatitis: An Update
Myoteri, D., Sakellariou, S., & TINIAKOS, D. G. (2025) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000500 · Cited by 9
Primary biliary cholangitis: current insights and novel therapies
Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 9
“These criteria tend to encompass patients with the strongest manifestations of the AIH-PBC variant syndrome, potentially underestimating its actual prevalence [57–59].”
Huang, L.-X., Wang, Z., Jin, R., Chen, H., & Feng, B. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2153672 · Cited by 14
“Additional therapy with corticosteroids plus UDCA could improve the biochemical response in such patients [100].”
BackgroundThe phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants
Bolis, F., Cazzaniga, G., Pagni, F., Invernizzi, P., Carbone, M., & Gerussi, A. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastrohep.2024.502225 · Cited by 9
Cholestatic Liver Disease Overlap Syndromes
Mayo, M. J. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.006 · Cited by 9
Overlap syndromes: An emerging diagnostic and therapeutic challenge
Malhotra, S., & Dhiman, P. (2014) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.145316 · Cited by 8
Non-invasive diagnosis and follow-up of autoimmune hepatitis
Lemoinne, S., Heurgué, A., Bouzbib, C., Hanslik, B., Gournay, J., Nguyen-Khac, É., Bureau, C., de Lédinghen, V., Ganne‐Carrié, N., & Bourlière, M. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101772 · Cited by 10
Nguyen, H. H., Fritzler, M. J., & Swain, M. G. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.914505 · Cited by 9
Primär biliäre Leberzirrhose und Overlap-Syndrome
Strassburg, C. P., & Manns, M. P. (2004) · Der Internist · doi:10.1007/s00108-003-1127-x · Cited by 8
The Therapeutic Role of Ursodeoxycholic Acid in Digestive Diseases
Gamboa, A. M., Tian, C., Massaad, J., Reshamwala, P. A., & Cai, Q. (2011) · Cited by 9
Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba
Castellanos, M., Hernández, D. L. R., Eugenio, D., Palanca, W., Guridi, Z. D., & Fabián, L. G. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.04.002 · Cited by 12
“The Chazouillères criteria were used for the diagnosis of AIH/PBC overlap syndrome.(10) Patients were excluded from the analysis if evidence of AILD diagnosis was insufficient or if their medical records were incomplete due to poor follow-up.”
MethodLindor, K. D., & Levy, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00041-3 · Cited by 9
Investigational drugs in early phase development for primary biliary cholangitis
Gochanour, E. M., & Kowdley, K. V. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1857364 · Cited by 9
(2016) · Springer Publishing Company eBooks · doi:10.1891/9780826117496.0019 · Cited by 8
Tanaka, A., Treeprasertsuk, S., Chang, M., Tan, S.-S., Efe, C., Jeong, S., Ma, X., Weltman, M., Isayama, H., & Jia, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10965-6 · Cited by 8
“Despite the widespread use of the “Paris Criteria” (1998) in clinical practice, a clear clinical or pathological definition of PBC-AIH overlap remains elusive [62] (Table 4).”
van Hooff, M. C., de Veer, R. C., Werner, E., Beuers, U. H., Drenth, J. P. H., Cuperus, F. J. C., van Hoek, B., Veldt, B. J., Klemt‐Kropp, M., van Meer, S., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003879 · Cited by 7
Grossar, L., Raevens, S., Steenkiste, C. V., Colle, I. O., Vloo, C. D., Orlent, H., Schouten, J. N. L., Gallant, M., Driessche, A. V., Lefere, S., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101149 · Cited by 10
Beretta‐Piccoli, B. T., Mieli‐Vergani, G., & Vergani, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00074-6 · Cited by 10
Ni, X., Lian, M., Wu, H., Li, X., Li, S., Bao, H., Miao, Q., Xiao, X., Guo, C., Li, H., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i1.80 · Cited by 7
Chang, M., Le, P., Chen, W., Chen, T., Su, C., Chen, C., Lin, C., Wu, C., Kuo, C., Kf, S., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16736 · Cited by 7
“40 Although not statistically signi fi cant, the PBC-AIH OS cohort had the highest cumulative incidence of cirrhosis among the AILD patients.”
Cirrhose biliaire primitive et grossesse
Ducarme, G., Bernuau, J., & Luton, D. (2013) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2013.03.016 · Cited by 7
A case of hepatitis E virus infection in a patient with primary biliary cholangitis
Inagaki, K., Takaki, S., Honda, Y., Inoue, M., Mori, N., Kawakami, H., Kawakami, Y., Kawakami, M., Okamoto, H., Tuji, K., et al. (2017) · Kanzo · doi:10.2957/kanzo.58.183 · Cited by 7
Review: Current status of therapy in autoimmune liver disease
Hirschfield, G. M., Al‐Harthy, N., & Heathcote, E. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08098966 · Cited by 7
“…be artificial since broadly it is suggested that 10% of those with primary biliary cirrhosis (PBC) will have features of autoimmune hepatitis (AIH) [Chazouilleres et al. 1998; Czaja, 1998], 10% of adults with AIH have radiological evidence for sclerosing cholangitis (SC) [Abdalian et al. 2008] and…”
BackgroundNew agents for immunosuppression
Jefremow, A., & Neurath, M. F. (2021) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2021.101763 · Cited by 7
Goyal, R. M., Bansal, B., Ayyad, M., Singh, A., Morales, E. M., Qureshi, I., Maan, M. H. A., & Gaglio, P. J. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102598 · Cited by 6
Cançado, G. G. L., Chen, B., Cameron, M., Houri, I., Leung, K. K., Gulamhusein, A. F., Hansen, B. E., & Hirschfield, G. M. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000798 · Cited by 7
“…hepatitis-PBC overlap syndrome, used as an exclusion criterion, was defined by the presence of a combination of biochemical, serological, and/or histological features consistent with autoimmune hepatitis as defined by Paris criteria, [28] or by the concomitant use of immunosuppressive therapy.”
Wang, X., Li, Y., Jiang, L., Zhou, M., Zhang, X., & Wen, H. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-03840-1 · Cited by 6
“Liver biopsy is indispensable for evaluating the extent of liver fibrosis and the diagnosis of AIH-PBC overlap syndrome [6].”
BackgroundMethodEngel, B., Assis, D. N., Bhat, M., Clusmann, J., Drenth, J. P. H., Gerussi, A., Londoño, M., Oo, Y. H., Schregel, I., Sebode, M., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101265 · Cited by 8
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Ishibashi, H., Nakanuma, Y., Ueno, Y., Egawa, H., Koike, K., Komori, A., Sakisaka, S., Shimoda, S., Shirabe, K., Zeniya, M., et al. (2012) · Kanzo · doi:10.2957/kanzo.53.633 · Cited by 7
Autoimmune hepatitis and complexities in management
Janmohamed, A., & Hirschfield, G. M. (2018) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101015 · Cited by 7
Saeki, C., Matsuzaki, J., Kuroda, M., Fujita, K., Ichikawa, M., Takizawa, S., Takano, K., Oikawa, T., Nakanuma, Y., Saruta, M., et al. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2022-000879 · Cited by 7
Wang, Z., Jin, R., Hao, M., Xie, Y., Liu, Z.-C., Wang, X., & Feng, B. (2022) · Medicine · doi:10.1097/md.0000000000031395 · Cited by 7
“However, only four patients with an IgG level of more than 2 ULN and ALT level of more than 5 ULN satisfied OS criteria according to Paris Standard.”
BackgroundMethodInfluentialTamimi, T., Sallam, M., Rayyan, D., Farah, R., Alkhulaifat, D., Al-Ani, A. T., Elmusa, R., Sharawi, S., Tanash, O., & Rayyan, Y. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020629 · Cited by 8
Fujinaga, Y., Namisaki, T., Tsuji, Y., Shibamoto, A., Kubo, T., Koizumi, A., Matsuda, T., Inoue, T., Iwai, S., Tomooka, F., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14192 · Cited by 7
Ohba, K., Omagari, K., Kusakari, C., Kadokawa, Y., Hayashida, K., Takeshima, F., Mizuta, Y., Murata, I., Nakanuma, Y., & Kohno, S. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-1301-1 · Cited by 6
“(7) advocated the use of immunosuppressive therapy in addition to treatment with UDCA for patients with overlap syndrome of PBC and AIH in order to obtain a biochemical response.”
BackgroundHimoto, T., Kadota, K., Fujita, K., Nomura, T., Morishita, A., Yoneyama, H., & Masaki, T. (2017) · PubMed · Cited by 9
Merabet, Y. B., Barbe, C., Heurgué–Berlot, A., Thévenot, T., Minello, A., Habersetzer, F., Samuel, D., Bernard‐Chabert, B., Weil, D., Renard, P., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06444-7 · Cited by 6
Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan
Fujita, K., Oura, K., Tadokoro, T., Nakahara, M., Tani, J., Morishita, A., Kobara, H., Tsutsui, K., Himoto, T., & Masaki, T. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02720-0 · Cited by 6
Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
Fujinaga, Y., Namisaki, T., Tsuji, Y., Suzuki, J., Murata, K., Takeda, S., Takaya, H., Inoue, T., Noguchi, R., Fujimoto, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179814 · Cited by 6
“The exclusion criteria were as follows: (i) presence of an autoimmune overlap syndrome [18], (ii) use of immunosuppressant medications such as prednisone and azathioprine, and (iii) clinical findings suggestive of concomitant liver disease (i.”
BackgroundJain, K., Rastogi, A., Thomas, S. S., & Bihari, C. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.03.005 · Cited by 6
Clinical analysis of liver transplantation in autoimmune liver diseases
Zhong, C., Xi, Z., & Xia, Q. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.01.001 · Cited by 6
Abbas, Z., Asim, M. A., Saeed, A., Siddiqui, B., & Abbas, M. (2021) · Cureus · doi:10.7759/cureus.19789 · Cited by 9
Long, J., Yang, S., Huang, M., Luo, P., Li, L., Tsuneyama, K., Ansari, A. A., Lü, L., Gershwin, M. E., Lian, Z., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6077 · Cited by 7
“Two or more of the following featuresarealso required fordiagnosingAIH: (1) levels of ALT in serum at least five timesULN, (2) serum immunoglobulin G (IgG) at least twice the ULN or positive for anti-smooth muscle antibody (ASMA), and (3) exhibiting interface hepatitis in liver pathology [6,9].”
BackgroundInfluentialVallone, T. M., Ditelberg, J. S., & Kaplan, M. M. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-1296-7 · Cited by 6
“criteria were (1) ALP at least two times the upper limit of normal or serum γ -glutamyl transpeptidase at least five times the upper limit of normal, (2) a positive AMA, and (3) florid bile duct lesions seen on liver biopsy.”
BackgroundMethodInfluentialRapid-onset Primary Biliary Cirrhosis Resembling Drug-induced Liver Injury
Sohda, T., SHIGA, H., Nakane, H., Nishizawa, S., Yoshikane, M., Anan, A., Suzuki, N., Irie, M., Iwata, K., Watanabe, H., et al. (2005) · Internal Medicine · doi:10.2169/internalmedicine.44.1051 · Cited by 6
The variant forms of cholestatic diseases involving small bile ducts in adults
Chazouillères, O. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80437-7 · Cited by 6
Self-citationChazouillères, O., & Housset, C. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch19a · Cited by 9
Self-citationHEPATIC DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS: COINCIDENCE OR CONVERGENCE
MACKAY, I. (2004) · Elsevier eBooks · doi:10.1016/b9-78-012433-9/01950-0387 · Cited by 6
PBC–AIH variant syndrome: emerging new terminology and a new approach to diagnosis and management
Sebode, M., & Gerussi, A. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001149 · Cited by 5
Taneja, S., Roy, A., Mehtani, R., Koshy, A., Jain, A., Shukla, A., Goel, A., Arora, A., Anand, A. C., Saraya, A., et al. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103474 · Cited by 5
Pérez, C., Gulamhusein, A. F., Carbone, M., Trivedi, P. J., van der Meer, A. J., Corpechot, C., Battezzati, P. M., Lammers, W. J., Cazzagon, N., Floreani, A., et al. (2021) · PubMed · doi:10.1097/meg.0000000000002029 · Cited by 3
Self-citationChallenges in the diagnosis and management of AIH-PBC syndrome
Gerussi, A., Invernizzi, P., & Carbone, M. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101224 · Cited by 5
Liang, P., Huang, Y., Hu, Z., Zhou, L., Cai, S., Zhong, J., & Dong, L. (2025) · Clinical Rheumatology · doi:10.1007/s10067-024-07273-z · Cited by 5
Rigopoulou, E. I., Lygoura, V., Gabeta, S., Gatselis, N., Giannoulis, G., & Dalekos, G. Ν. (2025) · Liver International · doi:10.1111/liv.70074 · Cited by 6
Aksoy, E. K., Yilmaz, B., & Köklü, S. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328359493e · Cited by 5
Autoimmune hepatitis and primary biliary cholangitis overlap syndrome after COVID-19
Cunha‐Silva, M., de França, E. V. C., Greca, R. D., Mazo, D. F. D. C., da Costa, L. B. E., de Moraes, P. B. S., Veiga, C. T., Assis‐Mendonça, G. R., Boin, I. D. F. S. F., Stucchi, R. S. B., et al. (2023) · Autopsy and Case Reports · doi:10.4322/acr.2023.422 · Cited by 5
Dias, B., Aguiar, A., Morais, C. I., & Nery, F. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002565 · Cited by 6
Taneja, S., Kumar, P., Mitra, S., Duseja, A. K., Minz, R. W., Das, A., Dhiman, R. K., & Chawla, Y. K. (2017) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2017.08.005 · Cited by 5
“2%.(21,22) These patients have more severe disease, younger age of presentation and worse outcome regarding response to therapy and liver-related mortality.”
BackgroundOpen challenges in the management of autoimmune hepatitis
Gerussi, A., Halliday, N., Carbone, M., Invernizzi, P., & Thorburn, D. (2020) · Minerva Gastroenterology · doi:10.23736/s1121-421x.20.02805-6 · Cited by 5
[Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].
(2021) · PubMed Central · doi:10.3760/cma.j.cn112138-20211112-00794 · Cited by 8
Interstitial Lung Disease in Primary Biliary Cholangitis: A Cohort Prospective Study
Kalashnikov, M., Анатольевна, А. Л., Brovko, M., Sholomova, V. I., Yanakaeva, A., Тинович, А. Д., & Moiseev, S. V. (2023) · Life · doi:10.3390/life13020416 · Cited by 8
Overlap syndrome triggered by acute viral hepatitis A
Heurgué, A., Bernard‐Chabert, B., Picot, R., Cadiot, G., & Thiéfin, G. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282ffda23 · Cited by 5
Kakar, S. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06803-4.00026-5 · Cited by 5
Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2537192 · Cited by 4
“● Diagnosis of Primary Biliary Cholangitis (PBC) is based on clinical, biochemical, and serological markers, with liver biopsy recommended in specific cases. showing florid bile duct lesions [9].”
Umemura, M., Nagasaka, A., Fukasawa, Y., Fujita, Y., Endo, A., Nakamura, M., Nishikawa, S., & Higuchi, A. (2013) · Kanzo · doi:10.2957/kanzo.54.44 · Cited by 4
Wang, T., Takikawa, Y., Suzuki, K., Kuroda, H., Kakisaka, K., & Chiba, T. (2024) · Hepatology Research · doi:10.1111/hepr.14045 · Cited by 4
“…for advanced HCC. Recent studies have shown the efficacy of sorafenib and lenvati-nib, representative molecular targeted drugs, in treating advanced HCC. 4–6 Sorafenib and lenvatinib were approved by the US Food and Drug Administration for HCC treatment in 2007 7 and 2015, 8 respectively.”
Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features
Mané, F., Cardoso, H., Liberal, R., Lopes, S., Pereira, P., Gonçalves, R., & Macedo, G. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.11.006 · Cited by 5
Variants of autoimmune liver diseases: how to diagnose? how to treat?
Janik, M. K., Wunsch, E., & Milkiewicz, P. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16408 · Cited by 8
Díaz-Ramírez, G. S., Rivera, D. F. J., Escobar-Cárdenas, D. M., Vargas-Potes, C. J., Rojas, C. A., & Rojas, N. (2023) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.907 · Cited by 4
Zhang, Z., Wang, J., Chen, Y., Li, Y., Zhu, L., Wang, H., Liu, Y., Liu, J., Yin, S., Tong, X., et al. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100215 · Cited by 4
Management of Patients with Primary Biliary Cirrhosis: A Practical Guide
Nishio, A., Neuberger, J., & Gershwin, M. E. (1999) · BioDrugs · doi:10.2165/00063030-199912030-00001 · Cited by 4
“In such cases, a trial of corticosteroids may be indicated.[23] Primary sclerosing cholangitis (PSC) has to be considered, particularly in patients with inflammatory bowel disease, but this rarely occurs in patients with PBC.”
BackgroundLee, Y. N., Kim, Y. S., Kim, S. G., Lim, J. H., Jeong, S. W., Jang, J. Y., Lee, S. H., Kim, H. S., Kim, B. S., & Kim, H. K. (2011) · The Korean Journal of Internal Medicine · Cited by 5
Kang, Y.-Z., Sun, X.-Y., Liu, Y., & Shen, Z. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i7.2236 · Cited by 4
Overlap syndrome: autoimmune hepatitis with primary biliary cirrhosis.
Arulprakash, S., Sasi, A. D., Bala, M. R., Pugazhendhi, T., & Kumar, S., V (2010) · PubMed · Cited by 4
Histological Findings of Autoimmune Hepatitis
Harada, K. (2014) · Springer eBooks · doi:10.1007/978-4-431-54789-1_4 · Cited by 4
“Chazouilleres’s criteria [37] (Paris criteria) has been used as the diagnostic criteria for this overlap syndrome, and the simplified AIH system of the IAIHG has been used as the criteria for the AIH feature in PBC.”
MethodComplete spectrum of AMA-M2 positive liver disease in north India
Minz, R. W., Kaur, N., Anand, S., Aggarwal, R., Saikia, B., Das, A., & Chawla, Y. K. (2011) · Hepatology International · doi:10.1007/s12072-011-9326-3 · Cited by 5
Washington, K., & Manns, M. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00008-x · Cited by 4
Talwalkar, J. A., & Lindor, K. D. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50046-2 · Cited by 4
« Overlap syndrome » cirrhose biliaire primitive — hépatite auto-immune : le temps de la maturité ?
Chazouillères, O. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89321-3 · Cited by 6
“lésions nécrotico-inflammatoires périportales (hépatite d’interface) ou lobulaires d’intensité moyenne ou sévère) [2].”
Self-citationTrauner, M., & Boyer, J. L. (1999) · Current Opinion in Gastroenterology · doi:10.1097/00001574-199905000-00006 · Cited by 4
Fan, X., Yang, F., Leyu, Z., & Yang, L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.020 · Cited by 4
Chatzipantelis, P., & Giatromanolaki, A. N. (2021) · PubMed · doi:10.1097/meg.0000000000001876 · Cited by 3
Diagnosis of Autoimmune Hepatitis
Kim, J. H. (2023) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2023.001 · Cited by 3
Lv, H., Deng, A., Chen, Y., & Su, Z. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0057-oa · Cited by 3
Ronca, V., Parente, A., Lytvyak, E., Hansen, B. E., Hirschfield, G. M., Bonder, A., Ebadi, M., Elwir, S., Alsaed, M., Milkiewicz, P., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101332 · Cited by 4
Baven‐Pronk, M. A. M. C., Marijnissen, C. J. M., Biewenga, M., Stättermayer, A. F., Tushuizen, M. E., & van Hoek, B. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102146 · Cited by 4
Gerussi, A., Sebode, M., Nofit, E., Stoelinga, A., Bernasconi, D. P., Leburgue, A., Invernizzi, P., Schramm, C., van Hoek, B., TINIAKOS, D. G., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001793 · Cited by 3
Cirrosis hepática por hepatitis autoinmune: Serie de casos y revisión de la literatura
Zubieta-Rodríguez, R., Gómez-Correa, J., & Rodríguez-Amaya, R. (2016) · Revista Médicas UIS · doi:10.18273/revmed.v29n2-2016015 · Cited by 4
Öztürk, Ö., DUARTE, S. D. D. S., BALABAN, H. Y., ŞİMŞEK, H., & Şener, B. (2022) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5512 · Cited by 3
“AMA can be negative in PBC patients with clinical and histopathological findings of PBC [11,12].”
BackgroundMethodResultInfluentialOverlap Syndromes with Autoimmune Hepatitis
Smith, A. D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_5 · Cited by 3
Koyama, M., Yamazaki, T., Joshita, S., Ito, A., Ono, K., Watanabe, T., Yamashita, Y., Sugiura, A., Kobayashi, M., Sato, Y., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6337-20 · Cited by 3
“Patients with concomitant acute liver injury from autoimmune hepatitis show particularly rapid disease progression (7).”
BackgroundGonzález, R. S., Washington, K., & Lohse, A. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00008-9 · Cited by 3
Braga, M. H., Cançado, G. G. L., Bittencourt, P. L., Couto, C. A., Guedes, L. V., Lima, A. M. C., Ferraz, M. L. G., Villela‐Nogueira, C. A., Nardelli, M. J., Faria, L. C., et al. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101105 · Cited by 4
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.